Global Molecular Diagnostics Market Strategic Research Report

The global molecular diagnostics market occupies a central position in modern healthcare infrastructure, encompassing technologies that detect and analyze biological markers at the nucleic acid level to diagnose infectious diseases, genetic disorders, oncology conditions, and pharmacogenomic profiles. Valued at approximately USD 17.8 billion in 2024, the market has matured considerably since the unprecedented COVID-19 testing surge of 2020–2022, yet continues to expand on the strength of diversified clinical demand, broader assay menus, and sustained investment in next-generation detection platforms. Molecular diagnostics now underpins clinical decision-making across hospital laboratories, reference centers, point-of-care settings, and direct-to-consumer genomics services, making it one of the most strategically significant segments within the broader in-vitro diagnostics industry.

Three forces are reshaping demand at a structural level. First, the rising global burden of antimicrobial resistance has compelled hospitals and public health agencies to adopt rapid, pathogen-specific molecular testing to guide antibiotic stewardship programs — a clinical imperative that directly expands test volume in both high-income and middle-income markets. Second, the accelerating adoption of companion diagnostics in oncology, where targeted therapies require validated molecular biomarker identification before treatment initiation, has created a high-value, recurring revenue stream tightly linked to pharmaceutical pipeline growth; with more than 200 targeted oncology agents under late-stage clinical development globally, this co-dependency between diagnostics and therapeutics will intensify through 2032. Third, the cost trajectory of next-generation sequencing (NGS) consumables continues to fall, enabling clinical-grade whole-exome and targeted panel sequencing to migrate from academic medical centers into community hospitals and commercial reference laboratories. On the restraint side, complex reimbursement environments — particularly in the United States and Western Europe — create pricing uncertainty for novel assay categories, slowing adoption timelines for otherwise well-validated technologies.

This report delivers a comprehensive strategic analysis of the global molecular diagnostics market across the 2025–2032 forecast horizon, with a validated 2024 base year. Coverage spans product type segmentation (PCR, NGS, isothermal amplification, in-situ hybridization, and DNA microarrays), application segmentation (infectious disease, oncology, pharmacogenomics, genetic testing, and blood screening), and granular regional and country-level forecasts. Corporate strategy teams evaluating portfolio expansion, investment analysts modeling sector performance, M&A advisors assessing target identification, and procurement managers benchmarking supplier strategies will find actionable, data-anchored intelligence throughout.